The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, will be showing its Magstim Rapid2 Therapy System at the Royal College of Psychiatry International Congress 2015 in Birmingham, UK, 29th June-2nd July.
Recently receiving FDA clearance for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States, the Magstim Rapid2 Therapy System is also currently being used by NHS trusts in the UK. Nottinghamshire Healthcare's Neuromodulation Unit was the first unit to utilise the innovative rTMS treatment to reduce the burden of resistant depression. Magstim’s Rapid2 Therapy System has been in use in Nottingham since July 2013 and is proving a valuable treatment for MDD. In addition, Northampton Healthcare NHS Foundation Trust is providing improved patient choice with rTMS therapy, allowing a new option that can be conducted in an outpatient setting, without the need for anaesthetic.
Neuro-imaging techniques have shown that people suffering from MDD commonly display reduced blood flow in the left dorsolateral pre-frontal cortex (DLPFC) and heightened activity in the limbic system, which plays an important role in regulating mood. The Magstim Rapid2 Therapy System provides an effective treatment option for patients who have failed to respond to traditional pharmaceutical medication for MDD by directly stimulating the DLPFC. Importantly, the technique is completely non-invasive and performed as an outpatient procedure, enabling patients to go about their daily lives following treatment.
The Royal College of Psychiatrists International Congress 2015 is a major international event reflecting the College’s high standards in education, training and research with streams on new research, psychopharmacology, neuropsychiatry, psychosis, treatment, clinical skills, management and leadership and new science. Now the biggest meeting of psychiatrists in the UK, the 2014 event attracted 2,500 delegates.
For further information please visit https://www.magstim.com/row-en/.
About The Magstim Company
The Magstim Company Limited design, develop and market medical devices used in neuroscience research labs and clinical psychiatry centres. It started trading in 1990 and has won the Queen’s Award for International trade. It has also featured in the ‘Fast Growth 50’ of Welsh Companies.
Magstim provide clinicians and researchers with state-of-the-art stimulation and monitoring equipment to facilitate the assessment, protection and improvement in function of the human nervous system, with effort focused on applications related to magnetic neurological stimulation and intra-operative nerve monitoring. The company has longstanding contacts with key opinion leaders within the clinical and academic sectors.